Switching From Adalimumab to a Biosimilar

EP: 1.The Need for Biosimilars in Inflammatory Diseases and Regulatory Requirements for Approval

EP: 2.An Overview of Adalimumab Biosimilars

EP: 3.The Pharmacological Aspects of Adalimumab Biosimilars

EP: 4.The Safety and Efficacy of Adalimumab Biosimilars in Inflammatory Diseases

EP: 5.Impact of the Launch of Adalimumab Biosimilars in Different Clinical and Pharmacy Settings

EP: 6.The Role of Pharmacy Benefit Managers and Payers in Accessing Adalimumab Biosimilars

EP: 7.Strategies to Increase Adalimumab Biosimilar Uptake in Clinical Practice

EP: 8.Selecting Between Adalimumab Biosimilars for Your Patients

Now Viewing

EP: 9.Switching From Adalimumab to a Biosimilar

EP: 10.Clinical Experience With Initiating Adalimumab Biosimilars

EP: 11.The Role of Health Care Providers on Encouraging Adalimumab Biosimilar Use

EP: 12.Copay Assistance Programs for Adalimumab Biosimilars

EP: 13.Common Questions From Patients About Adalimumab Biosimilars

EP: 14.The Role of Nurses and Support Personal in Educating Patient on Adalimumab Biosimilars

EP: 15.Resources for Patients and Providers on Adalimumab Biosimilars

This is a video synopsis/summary of a panel discussion involving Jamie T. Brogan, MSN, APRN, FNP-BC; Kostas Botsoglou, MD; Jordan Axelrad, MD, MPH; Sophia Humphreys, PharmD, MHA; and Peter Lio, MD.

An expert discusses the safe transition of patients from a reference product to a biosimilar. He emphasizes that although biosimilars may not be identical, they are sufficiently similar in every parameter. The primary concern during transition is ensuring coverage, as issues with insurance approval can disrupt medication supply. Preparing samples and ensuring insurance approval beforehand can prevent such interruptions.

Proactive patient education is crucial, as the speaker’s practice informed stable patients in advance about potential manufacturer switches. This preemptive communication helped patients anticipate changes and maintain confidence in the effectiveness and safety of the new product.

Another physician emphasizes the importance of patient education, particularly regarding the "nocebo effect" associated with biosimilars, which can lead to unnecessary treatment withdrawal. Educating patients about potential logistical challenges and reassuring them about product safety is essential.

Consistent education across all healthcare staff is emphasized to build patient confidence and prevent misinformation. Patient concerns about efficacy and safety can be addressed by reviewing clinical data and reassuring them of the equivalence of biosimilars to reference products.

Logistical challenges, such as ensuring timely medication delivery, are highlighted as critical for patient safety, as interruptions in treatment could lead to loss of disease control. Bridging programs and support services can help mitigate these logistical concerns and ensure continuity of care during transitions.

Video synopsis is AI-generated and reviewed by HCPLive editorial staff.